Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

2.49
+0.02000.81%
Post-market: 2.500.0100+0.40%18:34 EDT
Volume:8.71M
Turnover:21.62M
Market Cap:238.29M
PE:-2.74
High:2.49
Open:2.46
Low:2.37
Close:2.47
52wk High:11.46
52wk Low:1.07
Shares:95.70M
Float Shares:72.51M
Volume Ratio:2.13
T/O Rate:12.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9078
EPS(LYR):-0.9791
ROE:-74.02%
ROA:-44.09%
PB:1.86
PE(LYR):-2.54

Loading ...

Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints

Simply Wall St.
·
Dec 26, 2025

Rezolute Inc. Chief Medical Officer Brian Kenneth Roberts Acquires Common Shares

Reuters
·
Dec 18, 2025

Rezolute Inc. CFO Daron Evans Reports Acquisition of Common Shares

Reuters
·
Dec 16, 2025

Rezolute Inc. Chief Commercial Officer Sunil Ratilal Karnawat Acquires Common Shares

Reuters
·
Dec 16, 2025

Rezolute Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 12, 2025

Rezolute Inc : Jefferies Cuts Target Price to $4 From $20

THOMSON REUTERS
·
Dec 12, 2025

Top Midday Decliners

MT Newswires Live
·
Dec 12, 2025

Why Is XOMA Royalty Stock Sinking Thursday?

Benzinga_recent_news
·
Dec 12, 2025

Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial

Benzinga_recent_news
·
Dec 12, 2025

Top Midday Stories: Oracle Shares Tumble After Revenue Miss; Lilly's Next-Gen Weight-Loss Drug Hits Primary Endpoints

MT Newswires Live
·
Dec 12, 2025

Wedbush Downgrades Rezolute to Neutral From Outperform, Price Target is $1

MT Newswires Live
·
Dec 11, 2025

Rezolute Shares Plummet After Phase 3 Trial Fails to Meet Goals

Dow Jones
·
Dec 11, 2025

Rezolute Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $1 From $12

THOMSON REUTERS
·
Dec 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill

Reuters
·
Dec 11, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
Dec 11, 2025

Rezolute Exec Says Nothing Heard From FDA Related to Congenital Study Impacting Tumor Study

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says Two Patients Who Discontinued Due to Serious Hypersensitivity Reactions Did Not Have Positive Anti-Drug Antibodies - Conf Call

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says FDA Discussion Will Be Completely Focused on Congenital Indication

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says of 63 Enrolled Participants, Four Patients Early Terminated Study Due to Adverse Events

THOMSON REUTERS
·
Dec 11, 2025

Rezolute Exec Says More Than 50 Patients Still on Open Label Extension Study

THOMSON REUTERS
·
Dec 11, 2025